文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿替利珠单抗辅助治疗早期三阴性乳腺癌:ALEXANDRA/IMpassion030随机临床试验

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-30

这项在31个国家330多个中心开展的国际随机3期试验,纳入2199例接受手术的II或III期三阴性乳腺癌患者,1:1随机接受20周标准化疗联合或不联合阿替利珠单抗(最多1年)。中位随访32个月,阿替利珠单抗联合化疗组与单纯化疗组无浸润性疾病生存事件分别为141例(12.8%)和125例(11.4%),分层风险比为1.11(95%CI 0.87-1.42;P=0.38)。结论:术后化疗联合阿替利珠单抗未带来获益。

要点

  • 阿替利珠单抗联合化疗组与单纯化疗组的浸润性疾病生存事件分别为141例(12.8%)和125例(11.4%)。
  • 最终分层无浸润性疾病生存风险比为1.11(95%CI 0.87-1.42;P=0.38)。
  • 阿替利珠单抗联合化疗组治疗相关3或4级不良事件发生率为54%,单纯化疗组为44%。

核心结论

  • 术后化疗联合阿替利珠单抗在复发高风险三阴性乳腺癌患者中未提供获益。

研究设计与样本

  • 开放标签国际随机3期试验,在31个国家330多个中心开展。
  • 纳入2018年8月2日至2022年11月11日期间接受手术作为初始治疗的II或III期三阴性乳腺癌患者。
  • 患者1:1随机接受20周标准化疗联合(n=1101)或不联合(n=1098)阿替利珠单抗,阿替利珠单抗用药最多1年。
  • 主要终点为无浸润性疾病生存,即随机化至同侧或对侧乳腺浸润性癌、身体其他部位复发或任何原因死亡的时间。
  • 研究独立数据监测委员会在2199例(计划2300例)时停止入组,所有患者在计划的早期中期和无效性分析后停止阿替利珠单抗,试验提前进行最终分析。

主要发现

  • 中位年龄53岁,多数自报为亚洲或白人种族且非拉丁裔或西班牙裔。
  • 中位随访32个月,阿替利珠单抗联合化疗组141例(12.8%)发生无浸润性疾病生存事件,单纯化疗组125例(11.4%)。
  • 最终分层无浸润性疾病生存风险比为1.11(95%CI 0.87-1.42;P=0.38)。
  • 与单纯化疗相比,阿替利珠单抗联合化疗与更多治疗相关3或4级不良事件相关(54% vs 44%)。
  • 两组致死性不良事件发生率相似(0.8% vs 0.6%),导致化疗终止的不良事件发生率也相似,化疗暴露相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究独立数据监测委员会在2199例(计划2300例)时停止入组,试验提前进行最终分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- to 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative breast cancer was chemotherapy after surgery. However, it was not known whether the addition of immune therapy to postsurgery chemotherapy would be beneficial. OBJECTIVE: To evaluate the addition of immune therapy in the form of atezolizumab to postoperative chemotherapy in patients with the high-risk triple-negative breast cancer subtype. DESIGN, SETTING, AND PARTICIPANTS: In this open-label international randomized phase 3 trial conducted in more than 330 centers in 31 countries, patients undergoing surgery as initial treatment for stage II or III triple-negative breast cancer were enrolled between August 2, 2018, and November 11, 2022. The last patient follow-up was on August 18, 2023. INTERVENTIONS: Patients were randomized (1:1) to receive standard chemotherapy for 20 weeks with (n = 1101) or without (n = 1098) the immune therapy drug atezolizumab for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary end point was invasive disease-free survival (time between randomization and invasive breast cancer in the same or opposite breast, recurrence elsewhere in the body, or death from any cause). RESULTS: The median age of enrolled patients was 53 years and most self-reported as being of Asian or White race and neither Latino nor Hispanic ethnicity. The study independent data monitoring committee halted enrollment at 2199 of 2300 planned patients. All patients stopped atezolizumab following a planned early interim and futility analysis. The trial continued to a premature final analysis. With invasive disease-free survival events in 141 patients (12.8%) treated with atezolizumab-chemotherapy and 125 (11.4%) with chemotherapy alone (median follow-up, 32 months), the final stratified invasive disease-free survival hazard ratio was 1.11 (95% CI, 0.87-1.42; P = .38). Compared with chemotherapy alone, the regimen of atezolizumab plus chemotherapy was associated with more treatment-related grade 3 or 4 adverse events (54% vs 44%) but similar incidences of fatal adverse events (0.8% vs 0.6%) and adverse events leading to chemotherapy discontinuation. Chemotherapy exposure was similar in the 2 treatment groups. CONCLUSIONS AND RELEVANCE: The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03498716.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ignatiadis M, Bailey A, McArthur H, et al. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. JAMA. 2025. PMID: 39883436. doi:10.1001/jama.2024.26886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。